Table 1.
Renal hemodynamic responses to risk factors and therapies
| Exposure Variable | Ref. No. | Cohort | Duration of Therapy | GFR | RBF | FF | RA | RE | PGLO |
|---|---|---|---|---|---|---|---|---|---|
| SGLT2 inhibition | 18 | Adults with T1D | 8 wk | ↓ | / | / | ↑ | → | ↓ |
| Exenatide | 62 | Overweight adults without T2D | 120 min | ↑ | ↑ | / | ↓ | → | ↑ |
| Exenatide | 89 | Overweight adults with T2D | 150 min | → | → | → | ↑ | → | → |
| Manidipine | 67 | Adults with hypertension | 4 wk | / | / | / | ↓ | ↓ | ↓ |
| Plasma UA | 48 | Adults with T1D | N/A | ↓ | ↓ | → | ↓ | → | ↓ |
| Poor glycemic control | 92 | Adults with T2D | N/A | / | / | ↑ | / | / | ↑ |
| Hyperfiltration vs. normofiltration | 81 | Adults with T1D | N/A | ↑ | ↑ | ↑ | ↓ | → | ↑ |
GFR, glomerular filtration rate; RBF, renal blood flow; FF, filtration fraction; RA, afferent renal arteriolar resistance; RE, efferent renal arteriolar resistance; PGLO, glomerular hydrostatic pressure; SGLT2, sodium-glucose cotransport-2; T1d, type 1 diabetes; T2d, type 2 diabetes; UA, ; uric acid; ↑, increase; ↓, decrease; →, unchanged; /, not reported.